CUBN and Bruton-type agammaglobulinemia: Despite the fact that BTK-deficiency in patients with X-linked agammaglobulinemia (XLA) leads to loss of circulating mature B cells and serum Igs, no significant decrease in IgG levels has been reported in patients during the first 6 months of ibrutinib treatment, while it became evident after 12 months (60).